USC.edu
Are You a Patient?

Jay D. Desai, MD

Clinical Professor of Neurology and Pediatrics (Practitioner)

Image of Jay D. Desai, MD
Is this your profile? Click to edit
Phone +1 323 361 2471
Email [email protected]
CTSI Profile

Publications

  • Electrodiagnostic Studies as a Diagnostic and Prognostic Tool in Acute Flaccid Myelitis. Muscle Nerve. 2026 Aug; 74(2):411-421.. View in PubMed
  • Challenges in the Clinical Recognition of Acute Flaccid Myelitis and its Implications. J Pediatr. 2023 02; 253:55-62.e4.. View in PubMed
  • Factor Analysis of the Einstein Neonatal Neurobehavioral Assessment Scale in Infants with Congenital Heart Disease and Healthy Controls. J Child Neurol. 2022 10; 37(10-11):851-863.. View in PubMed
  • Safety of Diazepam Nasal Spray in Children and Adolescents With Epilepsy: Results From a Long-Term Phase 3 Safety Study. Pediatr Neurol. 2022 07; 132:50-55.. View in PubMed
  • Lack of clinically relevant differences in safety and pharmacokinetics after second-dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: A population analysis. Epilepsia. 2022 07; 63(7):1714-1723.. View in PubMed
  • Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. Epilepsia. 2021 10; 62(10):2485-2495.. View in PubMed
  • Consistent safety and tolerability of Valtoco® (diazepam nasal spray) in relationship to usage frequency in patients with seizure clusters: Interim results from a phase 3, long-term, open-label, repeat-dose safety study. Epilepsia Open. 2021 09; 6(3):504-512.. View in PubMed
  • Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study. Epilepsia. 2021 06; 62(6):1442-1450.. View in PubMed
  • Lack of observed tolerance to diazepam nasal spray (Valtoco®) after long-term rescue therapy in patients with epilepsy: Interim results from a phase 3, open-label, repeat-dose safety study. Epilepsy Behav. 2021 07; 120:107983.. View in PubMed
  • Lack of observed impact of history or concomitant treatment of seasonal allergies or rhinitis on repeated doses of diazepam nasal spray administered per seizure episode in a day, safety, and tolerability: Interim results from a phase 3, open-label, 12-month repeat-dose safety study. Epilepsy Behav. 2021 05; 118:107898.. View in PubMed

Similar People